Loading…

Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation

BACKGROUNDThe Central Drugs Standard Control Organization approved a bilayered, uncoated, fixed-dosage combination tablet formulation containing pregabalin (75 mg) and etoricoxib (60 mg) in November 2019 to control prolonged back pain with neuropathic components. OBJECTIVEThis research aims to creat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of AOAC International 2022-10, Vol.105 (6), p.1536-1547
Main Authors: Shah, Janvi, Kotadiya, Rajendra, Patel, Rashmin
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13
cites cdi_FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13
container_end_page 1547
container_issue 6
container_start_page 1536
container_title Journal of AOAC International
container_volume 105
creator Shah, Janvi
Kotadiya, Rajendra
Patel, Rashmin
description BACKGROUNDThe Central Drugs Standard Control Organization approved a bilayered, uncoated, fixed-dosage combination tablet formulation containing pregabalin (75 mg) and etoricoxib (60 mg) in November 2019 to control prolonged back pain with neuropathic components. OBJECTIVEThis research aims to create an analytical quality by design-assisted reversed phase (RP)-HPLC method for quantifying pregabalin and etoricoxib in tablet formulation. METHODSThe best chromatographic conditions were a Phenomenex C8 column (250 × 4.6 mm, 5.6 μm) and a mobile phase of 0.35% orthophosphoric acid -acetonitrile (1 + 1, by volume). A flow rate of 1 mL/min was used with a detection wavelength of 220 nm. RESULTSThe optimized reversed phase HPLC method was successfully validated by the International Conference on Hormonization guideline Q2(R1). Moreover, the percentage assay of pregabalin and etoricoxib tablet formulation was 99.05 and 100.02% w/w, respectively, using the validated RP-HPLC method. CONCLUSIONThe newly developed analytical quality by design-assisted RP-HPLC method has several advantages, including shortened analytical time (2.65 min and 7.45 min pregabalin and etoricoxib, respectively), efficient separation in terms of well-defined peaks, and a simple mobile phase combination. HIGHLIGHTSThe use of analytical quality by design principles and the design of the experiment tool allowed the detection of influential parameters critical for achieving the most favourable chromatographic conditions for accurately quantifying individual drugs using the RP-HPLC method. The compliance of the results with the ICH criteria validated the method. As a result, adopting the analytical quality by design methodology ensured the development of a more robust method that can generate consistent, dependable, and quality data throughout the process while also saving time.
doi_str_mv 10.1093/jaoacint/qsac082
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2682257230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2682257230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13</originalsourceid><addsrcrecordid>eNo1Uc1OwzAYqxBIjJ87xxy5lCVfs6Y9wtgAaYiB4Fwl6VfI1CVbkqL1ZXhWCoOTLcu2ZDlJLhi9YrTMxivppDY2jrdBalrAQTJiJeepKAEOB05zmmYg2HFyEsKKUs5yCqPk69rKto9Gy5Y8d7I1sSeqJ7cYzLtNb2TAmrw41YVIXpbp_XIxJY8YP1xNGud_EjaaKKP5RDIL0awH6ixxDVl6fJdqKLRE2prMovNGu51RZFDmZod1eusCkqlbK2P3sVepWoxk7vy6a3-ls-SokW3A8z88Td7ms9fpfbp4unuYXi9SDSKPKULGy5Jy2YhGFAUwyNkwkTdasQkXoAALynU5ERyAFjWCEqXIBErK6ESz7DS53PduvNt2GGK1NkFj20qLrgsV5AXAREBGByvdW7V3IXhsqo0fdvu-YrT6uaL6v6L6uyL7Buf5gO0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2682257230</pqid></control><display><type>article</type><title>Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation</title><source>Oxford Journals Online</source><creator>Shah, Janvi ; Kotadiya, Rajendra ; Patel, Rashmin</creator><creatorcontrib>Shah, Janvi ; Kotadiya, Rajendra ; Patel, Rashmin</creatorcontrib><description>BACKGROUNDThe Central Drugs Standard Control Organization approved a bilayered, uncoated, fixed-dosage combination tablet formulation containing pregabalin (75 mg) and etoricoxib (60 mg) in November 2019 to control prolonged back pain with neuropathic components. OBJECTIVEThis research aims to create an analytical quality by design-assisted reversed phase (RP)-HPLC method for quantifying pregabalin and etoricoxib in tablet formulation. METHODSThe best chromatographic conditions were a Phenomenex C8 column (250 × 4.6 mm, 5.6 μm) and a mobile phase of 0.35% orthophosphoric acid -acetonitrile (1 + 1, by volume). A flow rate of 1 mL/min was used with a detection wavelength of 220 nm. RESULTSThe optimized reversed phase HPLC method was successfully validated by the International Conference on Hormonization guideline Q2(R1). Moreover, the percentage assay of pregabalin and etoricoxib tablet formulation was 99.05 and 100.02% w/w, respectively, using the validated RP-HPLC method. CONCLUSIONThe newly developed analytical quality by design-assisted RP-HPLC method has several advantages, including shortened analytical time (2.65 min and 7.45 min pregabalin and etoricoxib, respectively), efficient separation in terms of well-defined peaks, and a simple mobile phase combination. HIGHLIGHTSThe use of analytical quality by design principles and the design of the experiment tool allowed the detection of influential parameters critical for achieving the most favourable chromatographic conditions for accurately quantifying individual drugs using the RP-HPLC method. The compliance of the results with the ICH criteria validated the method. As a result, adopting the analytical quality by design methodology ensured the development of a more robust method that can generate consistent, dependable, and quality data throughout the process while also saving time.</description><identifier>ISSN: 1060-3271</identifier><identifier>EISSN: 1944-7922</identifier><identifier>DOI: 10.1093/jaoacint/qsac082</identifier><language>eng</language><ispartof>Journal of AOAC International, 2022-10, Vol.105 (6), p.1536-1547</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13</citedby><cites>FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13</cites><orcidid>0000-0002-3851-8257 ; 0000-0002-5484-874X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Shah, Janvi</creatorcontrib><creatorcontrib>Kotadiya, Rajendra</creatorcontrib><creatorcontrib>Patel, Rashmin</creatorcontrib><title>Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation</title><title>Journal of AOAC International</title><description>BACKGROUNDThe Central Drugs Standard Control Organization approved a bilayered, uncoated, fixed-dosage combination tablet formulation containing pregabalin (75 mg) and etoricoxib (60 mg) in November 2019 to control prolonged back pain with neuropathic components. OBJECTIVEThis research aims to create an analytical quality by design-assisted reversed phase (RP)-HPLC method for quantifying pregabalin and etoricoxib in tablet formulation. METHODSThe best chromatographic conditions were a Phenomenex C8 column (250 × 4.6 mm, 5.6 μm) and a mobile phase of 0.35% orthophosphoric acid -acetonitrile (1 + 1, by volume). A flow rate of 1 mL/min was used with a detection wavelength of 220 nm. RESULTSThe optimized reversed phase HPLC method was successfully validated by the International Conference on Hormonization guideline Q2(R1). Moreover, the percentage assay of pregabalin and etoricoxib tablet formulation was 99.05 and 100.02% w/w, respectively, using the validated RP-HPLC method. CONCLUSIONThe newly developed analytical quality by design-assisted RP-HPLC method has several advantages, including shortened analytical time (2.65 min and 7.45 min pregabalin and etoricoxib, respectively), efficient separation in terms of well-defined peaks, and a simple mobile phase combination. HIGHLIGHTSThe use of analytical quality by design principles and the design of the experiment tool allowed the detection of influential parameters critical for achieving the most favourable chromatographic conditions for accurately quantifying individual drugs using the RP-HPLC method. The compliance of the results with the ICH criteria validated the method. As a result, adopting the analytical quality by design methodology ensured the development of a more robust method that can generate consistent, dependable, and quality data throughout the process while also saving time.</description><issn>1060-3271</issn><issn>1944-7922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNo1Uc1OwzAYqxBIjJ87xxy5lCVfs6Y9wtgAaYiB4Fwl6VfI1CVbkqL1ZXhWCoOTLcu2ZDlJLhi9YrTMxivppDY2jrdBalrAQTJiJeepKAEOB05zmmYg2HFyEsKKUs5yCqPk69rKto9Gy5Y8d7I1sSeqJ7cYzLtNb2TAmrw41YVIXpbp_XIxJY8YP1xNGud_EjaaKKP5RDIL0awH6ixxDVl6fJdqKLRE2prMovNGu51RZFDmZod1eusCkqlbK2P3sVepWoxk7vy6a3-ls-SokW3A8z88Td7ms9fpfbp4unuYXi9SDSKPKULGy5Jy2YhGFAUwyNkwkTdasQkXoAALynU5ERyAFjWCEqXIBErK6ESz7DS53PduvNt2GGK1NkFj20qLrgsV5AXAREBGByvdW7V3IXhsqo0fdvu-YrT6uaL6v6L6uyL7Buf5gO0</recordid><startdate>20221026</startdate><enddate>20221026</enddate><creator>Shah, Janvi</creator><creator>Kotadiya, Rajendra</creator><creator>Patel, Rashmin</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3851-8257</orcidid><orcidid>https://orcid.org/0000-0002-5484-874X</orcidid></search><sort><creationdate>20221026</creationdate><title>Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation</title><author>Shah, Janvi ; Kotadiya, Rajendra ; Patel, Rashmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Janvi</creatorcontrib><creatorcontrib>Kotadiya, Rajendra</creatorcontrib><creatorcontrib>Patel, Rashmin</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of AOAC International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Janvi</au><au>Kotadiya, Rajendra</au><au>Patel, Rashmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation</atitle><jtitle>Journal of AOAC International</jtitle><date>2022-10-26</date><risdate>2022</risdate><volume>105</volume><issue>6</issue><spage>1536</spage><epage>1547</epage><pages>1536-1547</pages><issn>1060-3271</issn><eissn>1944-7922</eissn><abstract>BACKGROUNDThe Central Drugs Standard Control Organization approved a bilayered, uncoated, fixed-dosage combination tablet formulation containing pregabalin (75 mg) and etoricoxib (60 mg) in November 2019 to control prolonged back pain with neuropathic components. OBJECTIVEThis research aims to create an analytical quality by design-assisted reversed phase (RP)-HPLC method for quantifying pregabalin and etoricoxib in tablet formulation. METHODSThe best chromatographic conditions were a Phenomenex C8 column (250 × 4.6 mm, 5.6 μm) and a mobile phase of 0.35% orthophosphoric acid -acetonitrile (1 + 1, by volume). A flow rate of 1 mL/min was used with a detection wavelength of 220 nm. RESULTSThe optimized reversed phase HPLC method was successfully validated by the International Conference on Hormonization guideline Q2(R1). Moreover, the percentage assay of pregabalin and etoricoxib tablet formulation was 99.05 and 100.02% w/w, respectively, using the validated RP-HPLC method. CONCLUSIONThe newly developed analytical quality by design-assisted RP-HPLC method has several advantages, including shortened analytical time (2.65 min and 7.45 min pregabalin and etoricoxib, respectively), efficient separation in terms of well-defined peaks, and a simple mobile phase combination. HIGHLIGHTSThe use of analytical quality by design principles and the design of the experiment tool allowed the detection of influential parameters critical for achieving the most favourable chromatographic conditions for accurately quantifying individual drugs using the RP-HPLC method. The compliance of the results with the ICH criteria validated the method. As a result, adopting the analytical quality by design methodology ensured the development of a more robust method that can generate consistent, dependable, and quality data throughout the process while also saving time.</abstract><doi>10.1093/jaoacint/qsac082</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3851-8257</orcidid><orcidid>https://orcid.org/0000-0002-5484-874X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1060-3271
ispartof Journal of AOAC International, 2022-10, Vol.105 (6), p.1536-1547
issn 1060-3271
1944-7922
language eng
recordid cdi_proquest_miscellaneous_2682257230
source Oxford Journals Online
title Analytical Quality by Design-Based Robust RP-HPLC Method for Quantitative Estimation of Pregabalin and Etoricoxib in Fixed-Dose Combination Tablet Formulation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A51%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analytical%20Quality%20by%20Design-Based%20Robust%20RP-HPLC%20Method%20for%20Quantitative%20Estimation%20of%20Pregabalin%20and%20Etoricoxib%20in%20Fixed-Dose%20Combination%20Tablet%20Formulation&rft.jtitle=Journal%20of%20AOAC%20International&rft.au=Shah,%20Janvi&rft.date=2022-10-26&rft.volume=105&rft.issue=6&rft.spage=1536&rft.epage=1547&rft.pages=1536-1547&rft.issn=1060-3271&rft.eissn=1944-7922&rft_id=info:doi/10.1093/jaoacint/qsac082&rft_dat=%3Cproquest_cross%3E2682257230%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c276t-e2349904af7f788212610044fcb15472b2e804c95742208de2b79737ea0105c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2682257230&rft_id=info:pmid/&rfr_iscdi=true